4 years ago

Quell Therapeutics Secures $156 Million to Advance Engineered Treg Cell Therapies

  • Quell Therapeutics, a UK and US-based developer of engineered T-regulatory (Treg) cell therapies, has raised $156 million in Series B funding

  • The round was co-led by Jeito Capital, Ridgeback Capital Investments, SV Health Investors, and Fidelity Management & Research Company LLC, with participation from founding investor Syncona

  • The company intends to use the funds to advance its pipeline in transplantation, neuroinflammatory diseases, and autoimmune diseases

  • Quell's lead candidate, QEL-001, is being developed to induce operational tolerance following liver transplantation, with the potential to protect the post-transplant liver without the need for chronic immunosuppressive medications.

      • ProblemHealthcare

      "People who need organ transplants have to take lifelong immunosuppressant drugs, which can have serious side effects."

      Solution

      "Quell Therapeutics is developing a new kind of cell therapy that uses engineered Treg cells to prevent organ rejection and eliminate the need for lifelong immunosuppressant drugs."

      Covered on